TFB Advisors LLC Sells 687 Shares of Pfizer Inc. $PFE

TFB Advisors LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,942 shares of the biopharmaceutical company’s stock after selling 687 shares during the period. TFB Advisors LLC’s holdings in Pfizer were worth $265,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Bessemer Group Inc. grew its position in Pfizer by 11.1% during the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock worth $3,358,000 after acquiring an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK grew its position in Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock worth $35,817,000 after acquiring an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp bought a new stake in Pfizer during the 1st quarter worth approximately $8,283,000. Westbourne Investments Inc. bought a new stake in Pfizer during the 1st quarter worth approximately $2,411,000. Finally, Bourne Lent Asset Management Inc. grew its position in Pfizer by 90.8% during the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after acquiring an additional 18,200 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Bank of America increased their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Morgan Stanley decreased their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $28.13.

Pfizer Stock Down 0.5%

NYSE:PFE opened at $24.72 on Thursday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $29.17. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $140.52 billion, a P/E ratio of 13.15, a P/E/G ratio of 0.82 and a beta of 0.55. The stock’s fifty day simple moving average is $24.88 and its 200-day simple moving average is $24.13.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the company earned $0.60 EPS. The firm’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.